These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 28132521)

  • 1. Direct Intracranial Injection of AAVrh8 Encoding Monkey β-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain.
    Golebiowski D; van der Bom IMJ; Kwon CS; Miller AD; Petrosky K; Bradbury AM; Maitland S; Kühn AL; Bishop N; Curran E; Silva N; GuhaSarkar D; Westmoreland SV; Martin DR; Gounis MJ; Asaad WF; Sena-Esteves M
    Hum Gene Ther; 2017 Jun; 28(6):510-522. PubMed ID: 28132521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice.
    Lahey HG; Webber CJ; Golebiowski D; Izzo CM; Horn E; Taghian T; Rodriguez P; Batista AR; Ellis LE; Hwang M; Martin DR; Gray-Edwards H; Sena-Esteves M
    Mol Ther; 2020 Oct; 28(10):2150-2160. PubMed ID: 32592687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease.
    Bradbury AM; Gray-Edwards HL; Shirley JL; McCurdy VJ; Colaco AN; Randle AN; Christopherson PW; Bird AC; Johnson AK; Wilson DU; Hudson JA; De Pompa NL; Sorjonen DC; Brunson BL; Jeyakumar M; Platt FM; Baker HJ; Cox NR; Sena-Esteves M; Martin DR
    Exp Neurol; 2015 Jan; 263():102-12. PubMed ID: 25284324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease.
    McCurdy VJ; Rockwell HE; Arthur JR; Bradbury AM; Johnson AK; Randle AN; Brunson BL; Hwang M; Gray-Edwards HL; Morrison NE; Johnson JA; Baker HJ; Cox NR; Seyfried TN; Sena-Esteves M; Martin DR
    Gene Ther; 2015 Feb; 22(2):181-9. PubMed ID: 25474439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
    Tsuji D
    Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy.
    Bradbury AM; Cochran JN; McCurdy VJ; Johnson AK; Brunson BL; Gray-Edwards H; Leroy SG; Hwang M; Randle AN; Jackson LS; Morrison NE; Baek RC; Seyfried TN; Cheng SH; Cox NR; Baker HJ; Cachón-González MB; Cox TM; Sena-Esteves M; Martin DR
    Mol Ther; 2013 Jul; 21(7):1306-15. PubMed ID: 23689599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system.
    Rockwell HE; McCurdy VJ; Eaton SC; Wilson DU; Johnson AK; Randle AN; Bradbury AM; Gray-Edwards HL; Baker HJ; Hudson JA; Cox NR; Sena-Esteves M; Seyfried TN; Martin DR
    ASN Neuro; 2015; 7(2):. PubMed ID: 25873306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective gene therapy in an authentic model of Tay-Sachs-related diseases.
    Cachón-González MB; Wang SZ; Lynch A; Ziegler R; Cheng SH; Cox TM
    Proc Natl Acad Sci U S A; 2006 Jul; 103(27):10373-10378. PubMed ID: 16801539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic benefit after intracranial gene therapy delivered during the symptomatic stage in a feline model of Sandhoff disease.
    McCurdy VJ; Johnson AK; Gray-Edwards HL; Randle AN; Bradbury AM; Morrison NE; Hwang M; Baker HJ; Cox NR; Sena-Esteves M; Martin DR
    Gene Ther; 2021 Apr; 28(3-4):142-154. PubMed ID: 32884151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adeno-associated virus-mediated expression of β-hexosaminidase prevents neuronal loss in the Sandhoff mouse brain.
    Sargeant TJ; Wang S; Bradley J; Smith NJ; Raha AA; McNair R; Ziegler RJ; Cheng SH; Cox TM; Cachón-González MB
    Hum Mol Genet; 2011 Nov; 20(22):4371-80. PubMed ID: 21852247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment.
    Toro C; Zainab M; Tifft CJ
    Neurosci Lett; 2021 Nov; 764():136195. PubMed ID: 34450229
    [No Abstract]   [Full Text] [Related]  

  • 12. Adeno-Associated Virus Gene Therapy in a Sheep Model of Tay-Sachs Disease.
    Gray-Edwards HL; Randle AN; Maitland SA; Benatti HR; Hubbard SM; Canning PF; Vogel MB; Brunson BL; Hwang M; Ellis LE; Bradbury AM; Gentry AS; Taylor AR; Wooldridge AA; Wilhite DR; Winter RL; Whitlock BK; Johnson JA; Holland M; Salibi N; Beyers RJ; Sartin JL; Denney TS; Cox NR; Sena-Esteves M; Martin DR
    Hum Gene Ther; 2018 Mar; 29(3):312-326. PubMed ID: 28922945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of GM2 Gangliosidosis in Adult Sandhoff Mice Using an Intravenous Self-Complementary Hexosaminidase Vector.
    Osmon KJ; Thompson P; Woodley E; Karumuthil-Melethil S; Heindel C; Keimel JG; Kaemmerer WF; Gray SJ; Walia JS
    Curr Gene Ther; 2022; 22(3):262-276. PubMed ID: 34530708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis.
    Lemieux MJ; Mark BL; Cherney MM; Withers SG; Mahuran DJ; James MN
    J Mol Biol; 2006 Jun; 359(4):913-29. PubMed ID: 16698036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies.
    Leal AF; Benincore-Flórez E; Solano-Galarza D; Garzón Jaramillo RG; Echeverri-Peña OY; Suarez DA; Alméciga-Díaz CJ; Espejo-Mojica AJ
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversibility of neuropathology in Tay-Sachs-related diseases.
    Cachón-González MB; Wang SZ; Ziegler R; Cheng SH; Cox TM
    Hum Mol Genet; 2014 Feb; 23(3):730-48. PubMed ID: 24057669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volume and Infusion Rate Dynamics of Intraparenchymal Central Nervous System Infusion in a Large Animal Model.
    Taghian T; Horn E; Shazeeb MS; Bierfeldt LJ; Tuominen SM; Koehler J; Fernau D; Bertrand S; Frey S; Cataltepe OI; Gounis MJ; Abayazeed AH; Flotte TR; Sena-Esteves M; Gray-Edwards HL
    Hum Gene Ther; 2020 Jun; 31(11-12):617-625. PubMed ID: 32363942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.
    Karumuthil-Melethil S; Nagabhushan Kalburgi S; Thompson P; Tropak M; Kaytor MD; Keimel JG; Mark BL; Mahuran D; Walia JS; Gray SJ
    Hum Gene Ther; 2016 Jul; 27(7):509-21. PubMed ID: 27197548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of enzyme-bearing cells in GM2 gangliosidosis mice: regionally specific pattern of cellular infiltration following bone marrow transplantation.
    Oya Y; Proia RL; Norflus F; Tifft CJ; Langaman C; Suzuki K
    Acta Neuropathol; 2000 Feb; 99(2):161-8. PubMed ID: 10672323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases.
    Ou L; Przybilla MJ; Tăbăran AF; Overn P; O'Sullivan MG; Jiang X; Sidhu R; Kell PJ; Ory DS; Whitley CB
    Gene Ther; 2020 May; 27(5):226-236. PubMed ID: 31896760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.